Humenotropin HP 150IU Injection contains Menotrophin, a highly purified gonadotropin preparation with a potency of 150 International Units (IU). Menotrophin is a combination of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) derived from the urine of postmenopausal women, used primarily to stimulate ovarian follicular development in women undergoing assisted reproductive technologies such as in vitro fertilization (IVF) or intrauterine insemination (IUI). It is also indicated for the treatment of anovulation in women who do not respond to clomiphene citrate and for inducing spermatogenesis in men with hypogonadotropic hypogonadism. The administration of Humenotropin HP 150IU Injection should be conducted under strict medical supervision, with dosing individualized according to patient response and monitored by hormone levels and ultrasound assessments. Adverse effects may include ovarian hyperstimulation syndrome (OHSS), multiple pregnancies, injection site reactions, and mild systemic symptoms such as headache or fatigue. Contraindications include primary ovarian failure, uncontrolled thyroid or adrenal dysfunction, and hormone-sensitive malignancies. Proper patient selection and adherence to recommended protocols are essential to maximize therapeutic outcomes while minimizing risks. Storage should be at controlled room temperature, protected from light, and the solution should be inspected visually for particulate matter before use.